Inaedis is revolutionizing the biopharmaceutical industry with our groundbreaking Rapid Room-Temperature Dehydration Technology (RTAD). As a Princeton University spin-out founded in 2022, we've developed a proprietary process that transforms liquid bioformulations into room-temperature stable powders, eliminating the need for costly and complex cold chain logistics. Our innovative approach not only simplifies manufacturing, packaging, and storage of vaccines, proteins, monoclonal antibodies, and gene therapies but also dramatically improves global access to these critical biologics. With a laboratory-scale prototype capable of producing over 1000 dry powder vaccine doses per batch and validation through a third-party blind study with a top 10 pharmaceutical company, Inaedis is poised to transform healthcare delivery worldwide, particularly in regions with limited infrastructure.
What is the problem?
The global distribution of vaccines and biologics faces a critical challenge: the cold chain. This complex, expensive, and environmentally unsustainable system of temperature-controlled storage and transportation is prone to failures, leading to significant product wastage and limited access to life-saving medications. For patients, especially in underserved regions, this means reduced availability of crucial treatments and increased healthcare inequity. Many areas lack the necessary infrastructure to maintain proper cold chain conditions, particularly in developing countries or remote locations. Economically, the cold chain imposes a substantial burden on healthcare systems, with annual losses due to temperature excursions estimated in billions globally. Moreover, it restricts the development of alternative, potentially more effective drug delivery methods, such as inhaled, nasal, or microneedle patch formulations, limiting innovation in pharmaceutical development and patient care.
What is their solution?
Inaedis has developed a groundbreaking solution: our proprietary Rapid Room-Temperature Dehydration Technology (RTAD). This innovative process converts liquid bioformulations into room-temperature stable powders, eliminating the need for cold chain logistics. Our technology preserves the efficacy of vaccines and biologics while extending their shelf life, making them more accessible worldwide. RTAD simplifies manufacturing, packaging, and storage processes, significantly reducing costs and environmental impact. Our powderized formulations enable alternative drug delivery methods, including inhaled, nasal, and microneedle patch applications, enhancing patient compliance and treatment efficacy. Inaedis' solution has been validated through a third-party blind study with a top 10 pharmaceutical company. By revolutionizing how biologics are prepared and distributed, Inaedis is transforming global healthcare delivery, particularly benefiting regions with limited infrastructure and resources.
